Bispecifics in Oncology Market Statistics Expected to Experience Major Growth by 2040, According to DelveInsight | AstraZeneca, I-MAB Biopharm, BioNTech, Bristol Myers Squibb

The Key Bispecifics in Oncology Companies in the market include - AstraZeneca, I-MAB Biopharma and BMS, BioNTech and Bristol Myers Squibb, and others.
DelveInsight's "Bispecifics in Oncology Market Insights, Epidemiology, and Market Forecast-2040 report offers an in-depth understanding of the Bispecifics in Oncology, historical and forecasted epidemiology as well as the Bispecifics in Oncology market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Bispecifics in Oncology, offering comprehensive insights into the Bispecifics in Oncology revenue trends, prevalence, and treatment landscape. The report delves into key Bispecifics in Oncology statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Bispecifics in Oncology therapies. Additionally, we cover the landscape of Bispecifics in Oncology clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Bispecifics in Oncology treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Bispecifics in Oncology space.

To Know in detail about the Bispecifics in Oncology market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bispecifics in Oncology Market Forecast [https://www.delveinsight.com/sample-request/bispecifics-in-oncology-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Bispecifics in Oncology Market Report:

*
The Bispecifics in Oncology market size is anticipated to grow with a significant CAGR during the study period (2020-2040)

*
Key Bispecifics in Oncology Companies: AstraZeneca, I-MAB Biopharma and BMS, BioNTech and Bristol Myers Squibb, and others

*
Key Bispecifics in Oncology Therapies: Volrustomig, Givastomig, BNT327, and others

*
The Bispecifics in Oncology market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bispecifics in Oncology pipeline products will significantly revolutionize the Bispecifics in Oncology market dynamics

*
As per DelveInsight's analysis, approximately 74,900 new cases of multiple myeloma were reported across the 7MM in 2024, with the number projected to increase throughout the forecast period.

*
In 2024, Germany and France reported the highest number of new multiple myeloma cases within the EU4 and the UK, together comprising about 24% of the total, while Spain registered the fewest cases.

*
In the United States, around 895,600 individuals were estimated to be eligible for bispecific antibody treatments in oncology

*
Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases, making it the predominant form of the disease.

*
In 2024, the 7MM recorded an estimated 211,550 new cases of gastric cancer, including gastroesophageal junction (GEJ) tumors, with projections indicating an increase by 2040.

*
According to the analysis, Japan reported around 121,910 new cases of NSCLC in 2024.

Bispecifics in Oncology Overview

Bispecifics in oncology refer to bispecific antibodies, a class of engineered therapeutic proteins designed to bind two different targets simultaneously. Unlike traditional monoclonal antibodies that attach to a single antigen, bispecific antibodies can engage both a tumor-associated antigen and an immune cell receptor, such as CD3 on T cells. This dual binding helps redirect the immune system to recognize and destroy cancer cells more effectively. Bispecifics are emerging as a powerful approach in cancer immunotherapy, with several approved therapies targeting conditions like leukemia and lymphoma, and many more in clinical development for solid tumors.

Get a Free sample for the Bispecifics in Oncology Market Forecast, Size & Share Analysis Report:

delveinsight.com/report-store/bispecifics-in-oncology-market-forecast [http://delveinsight.com/report-store/bispecifics-in-oncology-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Recent Developments In The Bispecifics in Oncology Treatment Landscape:

*
In July 2025, I-Mab reported the presentation of encouraging Phase Ib combination results for givastomig, administered alongside nivolumab and mFOLFOX6 for gastric cancer, at the 2025 European Society for Medical Oncology Gastrointestinal Cancers Congress.

*
In June 2025, BioNTech and Bristol Myers Squibb revealed a partnership to globally co-develop and co-commercialize BioNTech's investigational bispecific antibody BNT327 for multiple solid tumor types. Through this collaboration, both companies aim to expand and expedite the development of this clinical candidate.

Bispecifics in Oncology Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2040. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bispecifics in Oncology Epidemiology Segmentation:

The Bispecifics in Oncology market report proffers epidemiological analysis for the study period 2020-2040 in the 7MM segmented into:

*
Total Prevalence of Bispecifics in Oncology

*
Prevalent Cases of Bispecifics in Oncology by severity

*
Gender-specific Prevalence of Bispecifics in Oncology

*
Diagnosed Cases of Episodic and Chronic Bispecifics in Oncology

Download the report to understand which factors are driving Bispecifics in Oncology epidemiology trends @ Bispecifics in Oncology Epidemiology Forecast [https://www.delveinsight.com/sample-request/bispecifics-in-oncology-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Bispecifics in Oncology Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bispecifics in Oncology market or expected to get launched during the study period. The analysis covers Bispecifics in Oncology market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bispecifics in Oncology Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bispecifics in Oncology Therapies and Key Companies

*
Volrustomig: AstraZeneca

*
Givastomig: I-MAB Biopharma and BMS

*
BNT327: BioNTech and Bristol Myers Squibb

Discover more about therapies set to grab major Bispecifics in Oncology market share @ Bispecifics in Oncology Treatment Landscape [https://www.delveinsight.com/sample-request/bispecifics-in-oncology-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Bispecifics in Oncology Market Drivers

*
Rising prevalence of various cancers, including hematologic malignancies and solid tumors, increasing demand for innovative therapies

*
Growing adoption of immunotherapy and targeted cancer treatments, positioning bispecific antibodies as a promising approach

*
Advances in biotechnology and antibody engineering enabling the development of more effective and safer bispecific therapeutics

*
Increasing investments and collaborations among pharmaceutical companies to accelerate R&D and commercialization of bispecifics

Bispecifics in Oncology Market Barriers

*
High development and manufacturing costs associated with complex bispecific antibody production

*
Potential safety concerns, including cytokine release syndrome and off-target effects, which may limit clinical use

*
Challenges in optimizing dosing, stability, and delivery of bispecific antibodies for different cancer types

*
Stringent regulatory requirements and long approval timelines for novel oncology biologics

Scope of the Bispecifics in Oncology Market Report

*
Study Period: 2020-2040

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Bispecifics in Oncology Companies: AstraZeneca, I-MAB Biopharma and BMS, BioNTech and Bristol Myers Squibb, and others

*
Key Bispecifics in Oncology Therapies: Volrustomig, Givastomig, BNT327, and others

*
Bispecifics in Oncology Therapeutic Assessment: Bispecifics in Oncology current marketed and Bispecifics in Oncology emerging therapies

*
Bispecifics in Oncology Market Dynamics: Bispecifics in Oncology market drivers and Bispecifics in Oncology market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Bispecifics in Oncology Unmet Needs, KOL's views, Analyst's views, Bispecifics in Oncology Market Access and Reimbursement

To know more about Bispecifics in Oncology companies working in the treatment market, visit @ Bispecifics in Oncology Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/bispecifics-in-oncology-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Bispecifics in Oncology Market Report Introduction

2. Executive Summary for Bispecifics in Oncology

3. SWOT analysis of Bispecifics in Oncology

4. Bispecifics in Oncology Patient Share (%) Overview at a Glance

5. Bispecifics in Oncology Market Overview at a Glance

6. Bispecifics in Oncology Disease Background and Overview

7. Bispecifics in Oncology Epidemiology and Patient Population

8. Country-Specific Patient Population of Bispecifics in Oncology

9. Bispecifics in Oncology Current Treatment and Medical Practices

10. Bispecifics in Oncology Unmet Needs

11. Bispecifics in Oncology Emerging Therapies

12. Bispecifics in Oncology Market Outlook

13. Country-Wise Bispecifics in Oncology Market Analysis (2020-2040)

14. Bispecifics in Oncology Market Access and Reimbursement of Therapies

15. Bispecifics in Oncology Market Drivers

16. Bispecifics in Oncology Market Barriers

17. Bispecifics in Oncology Appendix

18. Bispecifics in Oncology Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bispecifics-in-oncology-market-statistics-expected-to-experience-major-growth-by-2040-according-to-delveinsight-astrazeneca-imab-biopharm-biontech-bristol-myers-squibb]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.